Davenport & Co’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Davenport & Co’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-19,450	Closed	-$647K	–	764
2020 Q2	$647K	Hold	19,450	–	–	0.01%	409
2020 Q1	$529K	Buy	19,450 +8,950	+85%	+$249K	0.01%	394
2019 Q4	$207K	Hold	10,500	–	–	﹤0.01%	673
2019 Q3	$131K	Hold	10,500	–	–	﹤0.01%	660
2019 Q2	$131K	Buy	+10,500	New	+$139K	﹤0.01%	663
2018 Q4	–	Sell	-8,000	Closed	-$210K	–	693
2018 Q3	$210K	Buy	+8,000	New	+$216K	﹤0.01%	638
2015 Q2	–	Sell	-56,559	Closed	-$860K	–	637
2015 Q1	$860K	Buy	+56,559	New	+$735K	0.01%	320

Other funds holding MNTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return

Davenport & Co's MNTA Position: Q3 2020 in Review

Davenport & Co sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q3 2020, closing a stake of 19,450 shares — an estimated $647K sold.

Davenport & Co first reported a position in MNTA in Q1 2015 and held it in 7 quarters. The position peaked at $860K in Q1 2015. 211 funds tracked by Wall St. Rank hold MNTA as of Q3 2020.

Davenport & Co reported no remaining Momenta Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
Davenport & Co sold 19,450 Momenta Pharmaceuticals, Inc. shares in Q3 2020, an estimated $647K.
Davenport & Co first reported a position in Momenta Pharmaceuticals, Inc. in Q1 2015 and held it in 7 quarters.
Davenport & Co's Momenta Pharmaceuticals, Inc. position peaked at $860K in Q1 2015.
211 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2020.

Based on Davenport & Co's 13F filing for Q3 2020, filed 15 Oct 2020.